InflaRx NV (IFRX)
0.8949
+0.07
(+8.42%)
USD |
NASDAQ |
Feb 06, 16:00
0.8722
-0.02
(-2.54%)
After-Hours: 20:00
InflaRx SG&A Expense (TTM) : 21.12M for Sept. 30, 2025
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| CDT Equity, Inc. | 14.67M |
| LENZ Therapeutics, Inc. | 60.86M |
| Liminatus Pharma, Inc. | 2.342M |
| Oruka Therapeutics, Inc. | 19.44M |
| Maze Therapeutics, Inc. | 31.47M |